nasopharyngeal carcinoma
Conditions
Interventions
Himena combined with concurrent radiotherapy and chemotherapy vs. concurrent chemoradiotherapy and chemotherapy:Nil
Sponsors
Sun Yat-Sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed patients with stage III~IV nasopharyngeal carcinoma confirmed by histopathology and imaging (see Appendix1); 2. Aged from 18 to 70; 3. KPS >= 70 (see Appendix 2); 4. Patients' lung, liver and kidney function, cardiac function, haematological indicators and urinary routine within normal limits. 5.no other radiotherapy sensitizer was used except ximena. 6.The use of sodium glyci-didazole has ended; 7.No other tumors, except cured cervical carcinoma in situ and basal skin carcinoma; 8.No AIDS, active tuberculosis and other serious immune disorders; 9. Treated with IMRT; 10.No chemotherapy drugs were used during the treatment. 11.Treatment and follow-up data were complete.
Exclusion criteria
Exclusion criteria: 1.Serious and uncontrolled diseases and infections; 2.Serious diseases of the heart, liver, kidney and other organs; 3.Previous or concurrent malignancy. 4.History of active hepatitis; 5.Treated with conventional radiotherapy techniques; 6.Obvious diseases that the investigator felt should be excluded from the study; 7.Other patients considered unsuitable for inclusion in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective mitigation rate ;Progression-free survival ;no distant metastasis for survival ;no local recurrence of the survival period;Total irradiation dose at total and partial remission; | — |
Countries
China
Contacts
Public ContactYun-fei Xia
Sun Yat-Sen University Cancer Center
Outcome results
None listed